Pfizer Inc’s (NYSE: PFE) COVID-19 vaccine that it developed in collaboration with German BioNTech is expected to receive full FDA approval on Monday – a few weeks ahead of the announced deadline of September 6th.
The drug regulatory authority refrained from commenting any further on the news first reported by the New York Times.
Despite the rising risk of the delta variant, only 60% of Americans aged 18 and above are fully vaccinated so far. Now that Pfizer receives full FDA approval, people that have been reluctant in getting vaccinated are likely to opt for it too.
UK orders 35 million doses of Pfizer’s vaccine
Also on Monday, the U.K. ordered another 35 million doses of Pfizer’s COVID-19 vaccine.
“While we continue to build this wall of defence from COVID-19, it’s also vital we do everything we can to protect the country for the future too – whether that’s from the virus as we know it or new variants,” health minister Sajid Javid said in a statement.
Here’s how much money Pfizer collected from COVID-19 vaccine shots in its latest reported quarter.
Pfizer to buy Canadian Trillium Therapeutics
In related news, Pfizer said on Monday it will acquire Trillium Therapeutics Inc for $2.26 billion after taking a $25 million stake in the Canadian drug developer last year. The $18.50 per share deal that will expand Pfizer’s footprint in blood cancer therapies translates to an over 200% premium on Trillium’s last closing price.
Pfizer picked the Bank of America Securities Inc as its financial adviser for the deal. Centerview Partners LLC is serving the role for Trillium.
Shares of Pfizer opened more than 3.0% up on Monday. Trillium stock was up about 200%.
The post Pfizer expecting full FDA approval for its COVID-19 vaccine today appeared first on Invezz.
from USA – Invezz https://ift.tt/2UGiZWJ
Wajeeh Khan
Click here to Join RICH DAD SUMMIT online with ROBERT KIYOSAKI - $1 Training for Passive Income: https://bit.ly/RichDadSummitWealthTraining
0 Comments